Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Bringing new therapy options to the hemophilia community.

Bensen-Kennedy D.

Thromb Res. 2013 Mar;131 Suppl 2:S15-8. doi: 10.1016/S0049-3848(13)70153-1.

PMID:
23537722
2.

Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.

Schulte S.

Thromb Res. 2013 Mar;131 Suppl 2:S2-6. doi: 10.1016/S0049-3848(13)70150-6. Review.

PMID:
23537723
3.

Pioneering designs for recombinant coagulation factors.

Schulte S.

Thromb Res. 2011;128 Suppl 1:S9-12. doi: 10.1016/S0049-3848(12)70003-8. Review.

PMID:
22221848
4.

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Zollner SB, Raquet E, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S.

Thromb Res. 2013 Aug;132(2):280-7. doi: 10.1016/j.thromres.2013.06.017. Epub 2013 Jul 5.

5.

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S.

J Thromb Haemost. 2014 Feb;12(2):220-8. doi: 10.1111/jth.12477.

6.
7.
8.

Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.

Golor G, Bensen-Kennedy D, Haffner S, Easton R, Jung K, Moises T, Lawo JP, Joch C, Veldman A.

J Thromb Haemost. 2013 Nov;11(11):1977-85. doi: 10.1111/jth.12409.

9.

The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII.

Pabinger-Fasching I.

Thromb Res. 2016 May;141 Suppl 3:S2-4. doi: 10.1016/S0049-3848(16)30414-5. Review.

10.

Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.

Zhang Y, Roberts J, Tortorici M, Veldman A, St Ledger K, Feussner A, Sidhu J.

J Thromb Haemost. 2017 Jun;15(6):1106-1114. doi: 10.1111/jth.13662. Epub 2017 Apr 21.

PMID:
28244200
11.

The promise and challenges of bioengineered recombinant clotting factors.

Pipe SW.

J Thromb Haemost. 2005 Aug;3(8):1692-701. Review.

12.

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.

Metzner HJ, Pipe SW, Weimer T, Schulte S.

Thromb Haemost. 2013 Nov;110(5):931-9. doi: 10.1160/TH13-03-0213. Epub 2013 Aug 29. Review.

PMID:
24178510
13.

Progress in the treatment of bleeding disorders.

Bergman GE.

Thromb Res. 2011 Jan;127 Suppl 1:S3-5. doi: 10.1016/j.thromres.2010.10.007. Epub 2010 Oct 29. Review.

PMID:
21035836
15.
16.

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.

Schaub RG.

Biochem Pharmacol. 2011 Jul 15;82(2):91-8. doi: 10.1016/j.bcp.2011.03.015. Epub 2011 Mar 29. Review.

PMID:
21453683
17.

Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.

Shapiro A.

Expert Opin Biol Ther. 2013 Sep;13(9):1287-97. doi: 10.1517/14712598.2013.819339. Review.

PMID:
23930915
18.

Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

Schmidbauer S, Witzel R, Robbel L, Sebastian P, Grammel N, Metzner HJ, Schulte S.

Thromb Res. 2015 Aug;136(2):388-95. doi: 10.1016/j.thromres.2015.05.005. Epub 2015 May 16.

PMID:
26037285
19.

Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.

Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR.

Thromb Haemost. 2002 May;87(5):925-6. No abstract available.

PMID:
12038803
20.

Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.

Den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K.

Haemophilia. 2009 Nov;15(6):1215-8. doi: 10.1111/j.1365-2516.2009.02079.x. Epub 2009 Aug 4.

PMID:
19686467

Supplemental Content

Support Center